A core epitope targeting antibody of SARS-CoV-2

查看全文 作　　者：Simeng [1]Zhao;Fengjiang [2,3]Liu;Shizhen [4]Qiu;Qiaoshuai [5]Lan;Yiran [1]Wu;Wei [5]Xu;Junzi [1,4]Ke;Jie [1,4]Yang;Xiaoyan [1]Liu;Kun [4]Wang;Hangtian [2]Guo;Shuai [5]Xia;Fangfang [1]Zhang;Jiabei [6]Wang;Xiaowen [7]Hu;Lu [5]Lu;Shibo [5]Jiang;Suwen [1,4]Zhao;Lianxin [8]Liu;Youhua [5]Xie;Xiuna [2]Yang;Haopeng [4]Wang;Guisheng [1,4]Zhong 机构地区：[1]iHuman Institute,ShanghaiTech University,Shanghai 201210,China;[2]Shanghai Institute for Advanced Immunochemical Studies,ShanghaiTech University,Shanghai 201210,China;[3]Innovative Center for Pathogen Research,Guangzhou Laboratory,Guangzhou 510005,China;[4]School of Life Science and Technology,ShanghaiTech University,Shanghai 201210,China;[5]Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences and Biosafety Level 3 Laboratory,Fudan University,Shanghai 200032,China;[6]Department of Hepatobiliary Surgery,Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery,The First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,The University of Science and Technology of China,Hefei 230001,China;[7]Department of Pulmonary and Critical Care Medicine,Division of Life Sciences and Medicine,The First Affiliated Hospital of USTC,The University of Science and Technology of China,Hefei 230026,China;[8]Division of Life Sciences and Medicine,The First Affiliated Hospital of USTC,The University of Sciences and Technology of China,Hefei 230001,China 出　　处：《Protein & Cell》索引2023年第14卷第1期,共5页 基　　金：supported by ShanghaiTech,Shanghai Frontiers Science Center for Biomacromolecules and Precision Medicine at ShanghaiTech University(G.Z.),and grants from the National Key Research and Development Program of China[Grant Nos.2017YFC1001301(G.Z.),2019YFA0111001(H.W.)];the National Natural Science Foundation of China[Nos.31670919(H.W.),81822045(L.L.)];Lingang Laboratory(No.LG202101-01-07 to X.Y.),Program of Shanghai Academic/Technology Research Leader[20XD1420300(L.L.)];Emergency response to new coronavirus infection scientific and technological project[YD9110002004(J.W.)],and Shanghai Sailing Program[20YF1430900(S.-M.Z.)]. 摘　　要：Dear Editor,Tremendous efforts have been made globally to develop therapeutics and prophylactics against severe acute respiratory syndrome coronavirus-2(SARS-CoV-2)which has caused thousands of millions of infections and deaths worldwide.A series of potent neutralizing antibodies with defined epitopes targeting RBD have been recently identified with different strategies.However,being an RNA virus,the instability of the SARS-CoV-2 genome results in numerous S-protein variants with altered viral phenotypes. 关 键 词：ACUTE RESPIRATORY globally